Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-09-28 pm EDT
44.43 USD   +0.77%
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/28Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China
RE
09/28Pfizer, BioNTech Seeks European Nod for COVID Vaccine Booster for Children 5 to 11
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Creighton students' COVID vaccine mandate appeal dismissed

08/12/2022 | 11:58am EDT

OMAHA, Neb. (AP) — The Nebraska Supreme Court on Friday dismissed an appeal by a handful of Creighton University students who sought to be exempt from the private Catholic school’s COVID-19 vaccine mandate last year, arguing that getting the shots would violate their religious beliefs against abortion.

The state’s high court said it didn’t have jurisdiction, citing its 150-year stance that people can't appeal orders denying or granting temporary injunctions. In this case, a judge last year declined to issue a temporary injunction that would have blocked Creighton University’s requirement that all students get the COVID-19 vaccination.

“Because the court’s denial of a temporary injunction was not a final order, we lack jurisdiction of the appeal and must dismiss it,” Justice William Cassel wrote for the court.

The 10 students who sought the injunction said they had religious objections to the vaccines because they "were developed and/or tested using abortion derived fetal cell lines.”

Laboratory-grown cell lines descended from fetuses that were aborted decades ago were used in some early-stage testing of the Pfizer and Moderna vaccines and to grow viruses used to manufacture the Johnson & Johnson vaccine. The vaccines do not contain fetal cells.

The Vatican declared in 2020 that it is “morally acceptable” for Roman Catholics to receive COVID-19 vaccines based on research that used cells derived from aborted fetuses when “ethically irreproachable” vaccines aren’t available.

Douglas County District Judge Marlon Polk said in his September 2021 ruling that he wouldn’t order the mandate be temporarily blocked because he didn't think the students would ultimately prevail in court. That's because the students had signed a form promising to get vaccinated once regulators fully approved one, the judge noted. The students appealed.

An attorney for the students, Robert Sullivan, said Friday that while he wished the state's high court had decided the appeal on its merits, the fact that it was decided on a technicality allows the students to continue their legal fight.

“The vast majority of the students want to move ahead with the case and see what we can get done,” Sullivan said. Most of the students went on to enroll at other schools, he said, while one had enough college credits to graduate over summer.

An attorney for the university did not immediately return a phone messages left Friday by The Associated Press seeking comment.

The private university in Omaha is affiliated with the Jesuit order of the Catholic Church, which teaches that abortion is a grave sin.

The university issued its mandate for students in August 2021, after the U.S. Food and Drug Administration granted full approval to the vaccine made by Pfizer. At the time, Creighton allowed only medical, not religious, exemptions to its vaccine requirements. However, the school added a religious exemption ahead of the 2022-23 academic year, Creighton spokesman Sam Achelpohl said.

Students refusing a vaccine on religious grounds must fill out a form and get approval from the university, according to the school's website.

Achelpohl declined to comment on Friday’s ruling or the ongoing lawsuit.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about PFIZER, INC.
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/28Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China
RE
09/28Pfizer, BioNTech Seeks European Nod for COVID Vaccine Booster for Children 5 to 11
MT
09/28Pfizer, BioNTech File European Medicines Agency Application for Omicron Booster Dose fo..
MT
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/27Japan's Shionogi says COVID pill reaches endpoint in Phase III trial
RE
09/27IDT Australia Names Acting CFO
MT
09/27Biohaven Pharmaceutical's Acquisition by Pfizer Likely to Close Oct. 3
MT
09/27Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formaliz..
AQ
09/27Fitch Revises Pfizer's Outlook to Positive; Affirms IDR at 'A'
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 739 M - -
Net cash 2022 10 262 M - -
P/E ratio 2022 7,85x
Yield 2022 3,65%
Capitalization 249 B 249 B -
EV / Sales 2022 2,35x
EV / Sales 2023 2,92x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 44,43 $
Average target price 55,75 $
Spread / Average Target 25,5%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-24.76%249 357
JOHNSON & JOHNSON-2.75%433 657
ELI LILLY AND COMPANY12.63%295 599
ROCHE HOLDING AG-17.54%259 622
ABBVIE INC.4.67%250 575
NOVO NORDISK A/S1.63%218 252